510(k) Guidance Footnote May Signal Greater FDA Oversight Of Preclinical Testing

Device industry experts say a seemingly minor footnote to the recent 510(k) program draft guidance could create a new requirement for nonclinical studies.

More from Clinical Trials

More from R&D